Letter to the Editor
Is the door open to further investigation with antiangiogenesis in SCLC?
Abstract
We thank Dr. Goto for his Editorial (1) on GOIRC-AIFA FARM6PMFJM study, the first randomized phase III trial evaluating the survival impact of bevacizumab combined to standard cisplatin-etoposide respect cisplatin-etoposide alone as first-line therapy of extended disease small cell lung cancer (SCLC) (2).
